Perioperative treatment with the new synthetic TLR-4 agonist GLA-SE reduces cancer metastasis without adverse effects

International Journal of Cancer

Volumn 138, Issue 7, 2016, Pages 1754-1764

  Matzner, Pini ^a   Sorski, Liat ^a   Shaashua, Lee ^a   Elbaz, Ely ^a   Lavon, Hagar ^a   Melamed, Rivka ^a   Rosenne, Ella ^a   Gotlieb, Neta ^b   Benbenishty, Amit ^a   Reed, Steve G ^c   Ben Eliyahu, Shamgar ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

CT26; GLA; in vivo; MADB106; metastases; NK; perioperative; stress; surgery; TLR 4

Indexed keywords

GLUCOPYRANOSYL LIPID A; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GLUCOPYRANOSYL LIPID-A; GLUCOSIDE; IMMUNOLOGICAL ADJUVANT; LIPID A; TOLL LIKE RECEPTOR 4;

ADAPTIVE IMMUNITY; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; BREAST ADENOCARCINOMA; CIRCULATION; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; EMULSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FISCHER 344 RAT; FLOW CYTOMETRY; GRANULOCYTE; INNATE IMMUNITY; LUNG; LUNG METASTASIS; LYMPHATIC SYSTEM; LYMPHOCYTE; MALE; METASTASIS; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; TUMOR CELL LINE; AGONISTS; ANIMAL; EXPERIMENTAL NEOPLASM; NEOPLASM METASTASIS; PATHOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; GLUCOSIDES; LIPID A; MALE; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; PERIOPERATIVE PERIOD; RATS; RATS, INBRED F344; TOLL-LIKE RECEPTOR 4;

EID: 84955719918     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29885     Document Type: Article

References (50)

1. Janeway CA Jr., Medzhitov R., Innate Immune Recognition. Annu Rev Immunol 2002; 20: 197-216.
2. Liu Y, Zeng G., Cancer and innate immune system interactions: translational potentials for cancer immunotherapy. J Immunother 2012; 35: 299-308.
3. Kumar H, Kawai T, Akira S., Toll-like receptors and innate immunity. Biochem Biophys Res Commun 2009; 388: 621-5.
4. Kawai T, Akira S., Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34: 637-50.
5. Basith S, Manavalan B, Yoo TH, et al., Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res 2012; 35: 1297-316.
6. Kaczanowska S, Joseph AM, Davila E., TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol 2013; 93: 847-63.
7. Adams S., Toll-like receptor agonists in cancer therapy. Immunotherapy 2009; 1: 949-64.
8. NCI. Immunotherapy Agent Workshop: U.S. Department of Health and Human Services 2007.
9. Azuma I, Seya T., Development of immunoadjuvants for immunotherapy of cancer. Int Immunopharmacol 2001; 1: 1249-59.
10. Tai LH, de Souza CT, Belanger S, et al., Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res 2013; 73: 97-107.
11. Neeman E, Ben-Eliyahu S., Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement. Brain Behav Immun 2013; 30 Suppl: S32-40.
12. Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S., Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat Rev Clin Oncol 2015; 12: 213-26.
13. Cho SY, Choi HY., Causes of death and metastatic patterns in patients with mammary cancer. Ten-year autopsy study. Am J Clin Pathol 1980; 73: 232-4.
14. World cancer report 2014: International Agency for Research on Cancer; 2014.
15. Poltorak A, He X, Smirnova I, et al., Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282: 2085-8.
16. Oblak A, Jerala R., Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol 2011; 2011: 609579
17. Ballas ZK, Rasmussen WL, Krieg AM., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996; 157: 1840-5.
18. Hunter CA, Gabriel KE, Radzanowski T, et al., Type I interferons enhance production of IFN-gamma by NK cells. Immunol Lett 1997; 59: 1-5.
19. Van Amersfoort ES, Van Berkel TJ, Kuiper J., Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 2003; 16: 379-414.
20. Naor R, Domankevich V, Shemer S, et al., Metastatic-promoting effects of LPS: sexual dimorphism and mediation by catecholamines and prostaglandins. Brain Behav Immun 2009; 23: 611-21.
21. Coler RN, Bertholet S, Moutaftsi M, et al., Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 2011; 6: e16333
22. Treanor JJ, Essink B, Hull S, et al., Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant. Vaccine 2013; 31: 5760-5.
23. Desborough JP., The stress response to trauma and surgery. Br J Anaesth 2000; 85: 109-17.
24. Ben-Eliyahu S., The promotion of tumor metastasis by surgery and stress: immunological basis and implications for psychoneuroimmunology. Brain Behav Immun 2003; 17 Suppl 1: S27-36.
25. Fox CB, Anderson RC, Dutill TS, et al., Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions. Colloids Surf B Biointerfaces 2008; 65: 98-105.
26. Fortier ME, Kent S, Ashdown H, et al., The viral mimic, polyinosinic:polycytidylic acid, induces fever in rats via an interleukin-1-dependent mechanism. Am J Physiol Regul Integr Comp Physiol 2004; 287: R759-66.
27. Arrode-Bruses G, Bruses JL., Maternal immune activation by poly I:C induces expression of cytokines IL-1beta and IL-13, chemokine MCP-1 and colony stimulating factor VEGF in fetal mouse brain. J Neuroinflamm 2012; 9: 83
28. Miyake T, Kumagai Y, Kato H, et al., Poly I:C-induced activation of NK cells by CD8 alpha+ dendritic cells via the IPS-1 and TRIF-dependent pathways. J Immunol 2009; 183: 2522-8.
29. Fujimoto C, Nakagawa Y, Ohara K, et al., Polyriboinosinic polyribocytidylic acid [poly(I:C)]/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes. Int Immunol 2004; 16: 55-63.
30. Rosenne E, Shakhar G, Melamed R, et al., Inducing a mode of NK-resistance to suppression by stress and surgery: a potential approach based on low dose of poly I-C to reduce postoperative cancer metastasis. Brain Behav Immun 2007; 21: 395-408.
31. Ben-Eliyahu S, Page GG, Yirmiya R, et al., Acute alcohol intoxication suppresses natural killer cell activity and promotes tumor metastasis. Nat Med 1996; 2: 457-60.
32. Kruschinski C, Hama Y, Skripuletz T, et al., In vivo monitoring of natural killer cell-dependent clearance of lung metastasis using dynamic positron emission tomography. In Vivo 2012; 26: 191-5.
33. Melamed R, Rosenne E, Shakhar K, et al., Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a beta-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav Immun 2005; 19: 114-26.
34. Melamed R, Rosenne E, Benish M, et al., The marginating-pulmonary immune compartment in rats: characteristics of continuous inflammation and activated NK cells. J Immunother 2010; 33: 16-29.
35. Shakhar G, Ben-Eliyahu S., In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. J Immunol 1998; 160: 3251-8.
36. Levi B, Benish M, Goldfarb Y, et al., Continuous stress disrupts immunostimulatory effects of IL-12. Brain Behav Immun 2011; 25: 727-35.
37. Corbett TH, Griswold DP, Jr., Roberts BJ, et al., Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 1975; 35: 2434-9.
38. Sorski L, Levi B, Shaashua L, et al., The impact of surgical extent and sex on the hepatic metastasis of colon cancer. Surg Today 2014; 44: 1925-34.
39. Goldfarb Y, Benish M, Rosenne E, et al., CpG-C oligodeoxynucleotides limit the deleterious effects of beta-adrenoceptor stimulation on NK cytotoxicity and metastatic dissemination. J Immunother 2009; 32: 280-91.
40. Chambers WH, Brumfield AM, Hanley-Yanez K, et al., Functional heterogeneity between NKR-P1bright/Lycopersicon esculentum lectin (L.E.)bright and NKR-P1bright/L.E.dim subpopulations of rat natural killer cells. J Immunol 1992; 148: 3658-65.
41. Creticos PS, Schroeder JT, Hamilton RG, et al., Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355: 1445-55.
42. Engel AL, Holt GE, Lu H., The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Expert Rev Clin Pharmacol 2011; 4: 275-89.
43. Faries MB, Hsueh EC, Ye X, et al., Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res 2009; 15: 7029-35.
44. Neeman E, Zmora O, Ben-Eliyahu S., A new approach to reducing postsurgical cancer recurrence: perioperative targeting of catecholamines and prostaglandins. Clin Cancer Res 2012; 18: 4895-902.
45. Shaashua L, Rosenne E, Neeman E, et al., Plasma IL-12 levels are suppressed in vivo by stress and surgery through endogenous release of glucocorticoids and prostaglandins but not catecholamines or opioids. Psychoneuroendocrinology 2014; 42: 11-23.
46. Rosenne E, Sorski L, Shaashua L, et al., In vivo suppression of NK cell cytotoxicity by stress and surgery: glucocorticoids have a minor role compared to catecholamines and prostaglandins. Brain Behav Immun 2014; 37: 207-19.
47. Meron G, Tishler Y, Shaashua L, et al., PGE2 suppresses NK activity in vivo directly and through adrenal hormones: effects that cannot be reflected by ex vivo assessment of NK cytotoxicity. Brain Behav Immun 2013; 28: 128-38.
48. Yang EV, Kim SJ, Donovan EL, et al., Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun 2009; 23: 267-75.
49. Sood AK, Bhatty R, Kamat AA, et al., Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 2006; 12: 369-75.
50. Ben-Eliyahu S, Shakhar G, Page GG, et al., Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and beta-adrenoceptors. Neuroimmunomodulation 2000; 8: 154-64.